IntravenousPremature labourAdult: Initially, 6.75 mg bolus (as 7.5 mg/mL soln) over 1 min, immediately followed by continuous infusion (as 0.75 mg/mL soln) of 0.3 mg/min for 3 hr, then 0.1 mg/min for up to 45 hr. Total duration: ≤48 hr. Max: 330.75 mg.
|
Soln for infusion: Withdraw 10 mL from a 100-mL bag of NaCl 0.9%, glucose 5% or Ringer’s lactate soln and replace w/ 10 mL of atosiban concentrate (using 2 vials of 37.5 mg/5 mL soln) to produce a final concentration of 0.75 mg/mL.
|
Gestational age <24 or >33 wk, premature rupture of membranes >30 wk of gestation, uterine haemorrhage requiring immediate delivery, eclampsia, severe pre-eclampsia, intra-uterine growth retardation w/ abnormal foetal heart rate, intra-uterine foetal death, suspected intra-uterine infection, placenta praevia, abruptio placentae.
|
Patient w/ abnormal placental site, intra-uterine growth restriction, multiple pregnancy. Hepatic impairment. Lactation.
|
Nausea, vomiting, headache, dizziness, flushes, tachycardia, hypotension, hyperglycaemia, inj site reactions; insomnia, pruritus, rash, pyrexia. Rarely, uterine haemorrhage and atony.
|
Monitor uterine contractions and foetal heart rate during use, and blood loss after delivery.
|
Increased risk of pulmonary oedema w/ other tocolytic drugs (e.g. Ca channel blockers, betamimetics).
|
Description:
Mechanism of Action: Atosiban, a synthetic oxytocin peptide analogue, is a competitive antagonist of oxytocin receptors. It suppresses uterine contractions by decreasing its frequency and the tone of uterine musculature. Additionally, it inhibits the effect of vasopressin.
Pharmacokinetics:
Distribution: Crosses the placenta and enters breast milk. Plasma protein binding: 46-48%.
Metabolism: Metabolised to 2 active metabolites.
Excretion: Via urine (small amount). Terminal half-life: 1.7 hr.
|
Store between 2-8°C. Protect from light.
|
|
|
G02CX01 - atosiban ; Belongs to the class of other gynecologicals. Used to inhibit uncomplicated premature labour between 24 and 33 weeks of gestation.
|
Anon. Atosiban. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 10/10/2016. Buckingham R (ed). Atosiban. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 10/10/2016. Joint Formulary Committee. Atosiban. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 10/10/2016.
|
Sign Out
